_____________________________________________________________________________________________________ *Corresponding author: E-mail: kaziaasim@gmail.com; Journal of Pharmaceutical Research International 33(44B): 34-54, 2021; Article no.JPRI.73863 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759) Designing of some Novel Methyl 2-((4- (Benzamido)Phenyl)Sulfanyl)-1,2,3,4-tetrahydro-6- Methylpyrimidine-5-carboxylate Derivatives as Potential Glucokinase Activators through Molecular Docking A. A. Kazi 1* and V. A. Chatpalliwar 1 1 Department of Pharmaceutical Chemistry, S.N.J.B’s S.S.D.J. College of Pharmacy, Neminagar, Chandwad, Nashik, Maharashtra-423101 India. Authors’ contributions This work was carried out in collaboration between both authors. Both authors read and approved the final manuscript. Article Information DOI: 10.9734/JPRI/2021/v33i44B32650 Editor(s): (1) Dr. Juan Carlos Troiano, University of Buenos Aires, Argentina. Reviewers: (1) Azibanasamesa D. C. Owaba, Niger Delta University, Nigeria. (2) Amit Gupta, Invertis University Bareilly, India. Complete Peer review History: https://www.sdiarticle4.com/review-history/73863 Received 05 July 2021 Accepted 15 September 2021 Published 21 September 2021 ABSTRACT Aims: Glucokinase (GK) is a cytoplasmic enzyme that metabolizes the glucose to glucose- 6- phosphate and supports the adjusting of blood glucose levels within the normal range in humans. In pancreatic β-cells, it plays a leading role by governing the glucose-stimulated secretion of insulin and in liver hepatocyte cells, it controls the metabolism of carbohydrates. GK acts as a promising drug target for the treatment of patients with type 2 diabetes mellitus (T2DM). Study Design: In the current study, the goal is to identify new substituted benzamide derivatives and test them via molecular docking as possible anti-diabetic drugs. Place and Duration of Study: The present work has been carried out at S.N.J.B’s S.S.D.J. College of Pharmacy, Neminagar, Chandwad, Nashik, Maharashtra, India during the time period of December-2020 to February-2021. Methodology: This work involved designing novel methyl 2-((4-(benzamido)phenyl)sulfanyl)- 1,2,3,4-tetrahydro-6-methylpyrimidine-5-carboxylate derivatives and their screening by molecular Original Research Article